首页> 外文期刊>Ophthalmic Research: Journal for Research in Experimental and Clinical Ophthalmology >Uveitis in juvenile idiopathic arthritis: recent therapeutic advances.
【24h】

Uveitis in juvenile idiopathic arthritis: recent therapeutic advances.

机译:幼年特发性关节炎中的葡萄膜炎:最近的治疗进展。

获取原文
获取原文并翻译 | 示例
           

摘要

Uveitis is a common association of juvenile idiopathic arthritis (JIA) that has previously been characterized by poor visual prognosis with limited options for effective treatment. Since corticosteroid treatment is not a preferred long-term option for most patients with this condition, systemic immunosuppressive therapy is frequently employed. The medical options for the treatment of JIA-associated uveitis have recently expanded beyond conventional immunosuppressive drugs to the biological agents. The biological drugs that are most commonly employed for JIA-associated uveitis are the tumor necrosis factor-α inhibitors. Other biological agents that have been used to treat the disease include drugs that target cytokine receptors, lymphocyte antigens and lymphocyte co-stimulation signals. This Mini Review highlights recent developments in the medical treatment of JIA-associated uveitis.
机译:葡萄膜炎是青少年特发性关节炎(JIA)的常见协会,以前的特征是视觉预后差,有效治疗的选择有限。由于皮质类固醇治疗不是大多数患有这种疾病的患者的长期选择,因此经常采用全身免疫抑制治疗。近来,用于治疗JIA相关性葡萄膜炎的医学选择已经从传统的免疫抑制药物扩展到了生物制剂。与JIA相关的葡萄膜炎最常使用的生物药物是肿瘤坏死因子-α抑制剂。已经用于治疗该疾病的其他生物制剂包括靶向细胞因子受体,淋巴细胞抗原和淋巴细胞共刺激信号的药物。本迷你评论重点介绍了JIA相关葡萄膜炎的医学治疗最新进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号